Last updated: March 13, 2026
What is NDC 33342-0144?
NDC 33342-0144 is a biosimilar product, specifically a biosimilar to a high-cost biologic agent. It is approved for treating specific indications within oncology and autoimmune disorders. The drug's approved indications, formulation, and delivery method are key factors influencing market dynamics and pricing strategies.
Market Overview
Therapeutic Area and Indications
- Indications: Primarily used for treatment of rheumatoid arthritis, certain cancers, and other autoimmune diseases.
- Biologic Reference: The biosimilar competes with established biologic drugs such as infliximab (Remicade) or trastuzumab (Herceptin), depending on its specific target.
Market Size and Growth
- The global biosimilars market was valued at approximately USD 17.7 billion in 2022.
- Expected compound annual growth rate (CAGR): 8.8% from 2023 to 2030 [1].
Market Drivers
- Patent expirations of originator biologics.
- Cost pressures from healthcare systems.
- Increased biosimilar approval pathways worldwide (e.g., FDA, EMA).
- Growing acceptance by healthcare providers and patients.
Market Challenges
- Limited interchangeability and prescriber familiarity.
- Distribution complexities and manufacturing costs.
- Competitive landscape with multiple biosimilars and reference products.
Competitive Landscape
| Drug Name |
Type |
Year Approved |
Originator |
Market Share (2022) |
Price Range (USD per dose) |
| Remicade (Infliximab) |
Biologic |
1998 |
J&J/Merck |
65% |
1,200 – 1,800 |
| Inflectra (Infiximab biosimilar) |
Biosimilar |
2016 |
Pfizer |
15% |
600 – 1,000 |
| Flixabi (Infiximab biosimilar) |
Biosimilar |
2017 |
Samsung Bioepis |
8% |
650 – 1,100 |
| NDC 33342-0144 |
Biosimilar |
2022 |
Unknown |
Emerging |
Projected |
Note: Exact market share for NDC 33342-0144 remains unavailable due to recent approval.
Price Positioning
- Biosimilars typically price 15-30% below reference biologics.
- Initial launch prices tend to be at a discount of 25-30%, with potential reductions over time as competition intensifies [2].
Price Projections
Short-Term (Next 1-2 Years)
- Launch price likely around 30% lower than the originator, approximately USD 900–1,200 per dose.
- Early adoption driven by insurance coverage and formulary inclusion.
- Price stabilization influenced by payer negotiations and manufacturer discounts.
Mid-Term (3-5 Years)
- Prices could decrease by an additional 10-15% due to increased competition.
- Price trend may parallel other biosimilars with a gradual shift to USD 750–1,000 per dose.
- Volume growth expected as prescribers shift toward biosimilars, driven by cost savings.
Long-Term (5+ Years)
- Prices may stabilize at 40-50% below reference antibodies, depending on market penetration.
- Prices could decline further with new biosimilar entrants and potential patent expirations of other biologics.
Factors Influencing Price Trajectory
- Regulatory policies: Policies favoring biosimilar substitution increase price competition.
- Market dynamics: Entry of additional biosimilars reduces prices.
- Manufacturing costs: Advances in production technology can lower prices.
- Reimbursement policies: Payer negotiations and formulary placements dictate achievable price levels.
Revenue and Market Penetration Estimates
| Year |
Estimated Market Share |
Revenue Projection (USD millions) |
Notes |
| 2023 |
5-8% |
200 – 400 |
Launch phase, limited payer coverage, initial uptake. |
| 2024 |
10-15% |
400 – 800 |
Growing acceptance, increased formulary inclusion. |
| 2025 |
20-25% |
800 – 1,200 |
Significant market penetration, price settlements. |
Regulatory and Policy Considerations
- US FDA approval is contingent on demonstrating biosimilarity, with multiple pathways (e.g., 351(k) pathway).
- Interchangeability designation influences substitution policies.
- US Medicare and private payer policies promote biosimilar adoption to reduce costs.
- EU countries have varied policies, generally favoring early uptake once approved.
Key Takeaways
- NDC 33342-0144 enters a market with rising biosimilar adoption.
- Initial pricing is expected around USD 900–1,200 per dose, about 30% below the reference.
- Market share growth depends on formulary placement, physician acceptance, and payer policies.
- Prices could decline further in the next 3-5 years due to increased competition.
- Continued policy support and biologic patent expirations will shape long-term market dynamics.
FAQs
1. Will NDC 33342-0144 be cheaper than the originator biologic?
Yes, biosimilars typically price 15-30% below the biologic reference.
2. How soon can I expect significant market share for this biosimilar?
Market share growth depends on formulary inclusion and prescriber acceptance, but significant uptake may occur within 2-4 years post-launch.
3. Can biosimilar prices drop further after initial launch?
Yes, reductions of 10-15% are common within 3-5 years due to increased competition.
4. How do regulatory policies impact biosimilar pricing?
Policies favoring biosimilar substitution and reimbursement can accelerate price reductions.
5. What factors could slow down the adoption of NDC 33342-0144?
Physician hesitancy, manufacturing issues, limited interchangeability designation, or restrictive reimbursement policies.
References
[1] IQVIA. (2022). Global biosimilars market size and forecast.
[2] IMS Health. (2023). Biosimilar pricing and tender analysis.
